GlassScriptPhysician profile
Ilango Dharmarajan
NPI 1528526464
$571.81
in general payments reported to CMS, 2019-2025
10 companies · $104 in 2025
The $104 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $160 · 2023: $132 · 2024: $177 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $412.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $159.72 | 2022 | |
| Insulet Corporation | $131.56 | 2023 | Omnipod |
| Eisai INC. | $79.42 | 2024-2025 | |
| Exact Sciences Corporation | $56.92 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Pfizer INC. | $41.53 | 2024 | |
| Lilly USA, LLC | $27.78 | 2024 | Kisunla |
| Novo Nordisk INC | $19.97 | 2024 | Ozempic, Rybelsus |
| Amgen INC. | $19.60 | 2024 | Prolia, Evenity |
| Otsuka America Pharmaceutical, INC. | $19.01 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $16.30 | 2025 | Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ilango Dharmarajan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.